Overdose Risk and Client Characteristics Associated With the Injection of Buprenorphine at a Medically Supervised Injecting Center in Sydney, Australia

References

• Aitken, C. K., Higgs, P. G., & Hellard, M. E. (2008). Buprenorphine injection in Melbourne, Australia – an update. Drug and Alcohol Review, 27(2), 197–199. doi:10.1080/09595230701829553
   PubMed Web of Science ®Google Scholar
• Alho, H., Sinclair, D., Vuori, E., & Holopainen, A. (2008). Abuse liability of buprenorphine naloxone tablets in untreated IV drug users. Drug and Alcohol Dependence, 88(1), 75–78. doi:10.1016/j.drugalcdep.2006.09.012
   Web of Science ®Google Scholar
• Bazazi, A., Yokell, M., Fu, J., Rich, J., & Zaller, N. (2011). Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. Journal of Addiction Medicine, 5(3), 175–180.
   PubMed Web of Science ®Google Scholar
• van Beek, I. (2003). The Sydney Medically Supervised Injecting Centre: A clinical model. Journal of Drug Issues, 33(3), 625–638. doi:10.1177/002204260303300305
   Web of Science ®Google Scholar
• Belackova, V., & Salmon, A. M. (2017). Overview of international literature – supervised injecting facilities and drug consumption rooms (Issue 1). Retrieved from Sydney Medically Supervised Injecting Centre.
   Google Scholar
• Bell, J. R., Butler, B., Lawrance, A., Batey, R., & Salmelainen, P. (2009). Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug and Alcohol Dependence, 104(1–2), 73–77. doi:10.1016/j.drugalcdep.2009.03.020
   PubMed Web of Science ®Google Scholar
• Blanchon, T., Boissonnas, A., Varescon, I., & Vidal-Trecan, G. (2003). Homelessness and high-dosage buprenorphine misuse. Substance Use and Misuse, 38(3–6), 429–442. doi:10.1081/JA-120017380
   PubMed Web of Science ®Google Scholar
• Boyd, J., Randell, T., Luurila, H., & Kuisma, M. (2003). Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiologica Scandinavica, 47(8), 1031–1033. doi:10.1034/j.1399-6576.2003.00201.x
   PubMed Web of Science ®Google Scholar
• Bursac, Z., Gauss, C., Williams, D., & Hosmer, D. (2008 ). Purposeful selection of variables in logistic regression. Source Code for Biology and Medicine, 3, 17.
   PubMedGoogle Scholar
• Comer, S. D., Sullivan, M. A., Vosburg, S. K., Manubay, J., Amass, L., Cooper, Z. D., … Kleber, H. D. (2010). Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction, 105(4), 709–718. doi:10.1111/j.1360-0443.2009.02843.x
   PubMed Web of Science ®Google Scholar
• Darke, S. (2016). Addiction classics: Heroin overdose. Addiction. doi:10.1111/add.13516
   Web of Science ®Google Scholar
• Darke, S., & Torok, M. (2013). Childhood physical abuse, non-suicidal self-harm and attempted suicide amongst regular injecting drug users. Drug and Alcohol Dependence, 133(2), 420–426. doi:10.1016/j.drugalcdep.2013.06.026
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., Larance, B., Bell, J. R., Winstock, A. R., Lintzeris, N., Ali, R. L., … Mattick, R. P. (2009). Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist–antagonist formulation. Medical Journal of Australia, 191(3), 161–165.
   PubMed Web of Science ®Google Scholar
• Genberg, B. L., Gillespie, M., Schuster, C. R., Johanson, C.-E., Astemborski, J., Kirk, G. D., … Mehta, S. H. (2013). Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. Addictive Behaviors, 38(12), 2868–2873. doi:10.1016/j.addbeh.2013.08.008
   PubMed Web of Science ®Google Scholar
• Hakansson, A., Medvedeo, A., Andersson, M., & Berglund, M. (2007). Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: Purpose of misuse and route of administration. European Addiction Research, 13(4), 207–215. doi:10.1159/000104883
   PubMed Web of Science ®Google Scholar
• IBM, Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.
   Google Scholar
• Islam, M. M., Topp, L., Conigrave, K. M., van Beek, I., Maher, L., White, A., … Day, C. A. (2012). The reliability of sensitive information provided by injecting drug users in a clinical setting: Clinician administered versus audio computer assisted self interviewing (ACASI). AIDS Care, 24(12), 1496–1503. doi:10.1080/09540121.2012.663886
   PubMed Web of Science ®Google Scholar
• Jauncey, M. E., van Beek, I., Salmon, A. M., & Maher, L. (2011). Bipartisan support for Australia’s supervised injecting facility: A decade in the making. Medical Journal of Australia, 195
   PubMed Web of Science ®Google Scholar
• Jenkinson, R., Clark, N., Fry, C., & Dobbin, M. (2005). Buprenorphine diversion and injection in Melbourne, Australia: An emerging issue? Addiction, 100(2), 197–205. doi:10.1111/j.1360-0443.2004.00958.x
   PubMed Web of Science ®Google Scholar
• Kimber, J., Mattick, R. P., Kaldor, J., van Beek, I., Gilmour, S., & Rance, J. A. (2008). Process and predictors of drug treatment referral and referral uptake at the Sydney Medically Supervised Injecting Centre. Drug and Alcohol Review, 27(6), 602–612. doi:10.1080/09595230801995668
   PubMed Web of Science ®Google Scholar
• Kintz, P. (2001). Deaths involving buprenorphine: A compendium of French cases. Forensic Science International, 121(1–2), 65–69. doi:10.1016/S0379-0738(01)00454-6
   PubMed Web of Science ®Google Scholar
• Larance, B., Degenhardt, L., Lintzeris, N., Bell, J., Winstock, A., Dietze, P., … Horyniak, D. (2011). Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. Drug and Alcohol Dependence, 118(2-3), 265–273. doi:10.1016/j.drugalcdep.2011.04.002
   PubMed Web of Science ®Google Scholar
• Larance, B., Lintzeris, N., Ali, R., Dietze, P., Mattick, R. P., Jenkinson, R., & Degenahrdt, L. (2014). The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug and Alcohol Dependence, 136(1), 21–27.
   Google Scholar
• Latimer, J., Ling, S., Flaherty, I., Jauncey, M., & Salmon, A. M. (2016). Risk of fentanyl overdose among clients of the Sydney Medically Supervised Injecting Centre. International Journal of Drug Policy, 37, 111–114. doi:10.1016/j.drugpo.2016.08.004
   PubMed Web of Science ®Google Scholar
• McBride, A. J., Pates, R. M., Arnold, K., & Ball, N. (2001). Needle fixation, the drug user's perspective: A qualitative study. Addiction, 96(7), 1049–1058. doi:10.1046/j.1360-0443.2001.967104914.x
   PubMed Web of Science ®Google Scholar
• Metrebian, N., Groshkova, T., Hellier, J., Charles, V., Martin, A., Forzisi, L., … Strang, J. (2015). Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: Secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT). Addiction, 110(3), 479–490. doi:10.1111/add.12748
   PubMed Web of Science ®Google Scholar
• Moratti, E., Kashanpour, H., Lombardelli, T., & Maisto, M. (2010). Intravenous misuse of buprenorphine: Characteristics and extent among patients undergoing drug maintenance therapy. Clinical Drug Investigation, 30(Suppl 1), 3–11.
   PubMedGoogle Scholar
• O'Keefe, D., Aitken, C., Higgs, P., & Dietze, P. (2013). Concordance between self-reported and actual hepatitis C virus infection status in a cohort of people who inject drugs. Drug and Alcohol Review, 32(2), 208–210. doi:10.1111/j.1465-3362.2012.00502.x
   PubMed Web of Science ®Google Scholar
• Ritter, A. (2001). Buprenorphine for the treatment of heroin dependence [editorial]. Drug and Alcohol Review, 20(1), 5–7. doi:10.1080/0959523020035240
   Web of Science ®Google Scholar
• Roxburgh, A., Darke, S., Salmon, A., Dobbins, T., & Jauncey, M. (2017). Frequency and severity of non-fatal opioid overdoses among clients attending the Sydney Medically Supervised Injecting Centre. Drug and Alcohol Dependence, 176, 126–132. doi:10.1016/j.drugalcdep.2017.02.027
   PubMed Web of Science ®Google Scholar
• Salmon, A. M., Dwyer, R., Jauncey, M., van Beek, I., Topp, L., & Maher, L. (2009). Injecting-related injury and disease among clients of a supervised injecting facility. Drug and Alcohol Dependence, 101(1-2), 132–136. doi:10.1016/j.drugalcdep.2008.12.002
   PubMed Web of Science ®Google Scholar
• Smirnov, A., & Kemp, R. (2012). Use and misuse of opioid replacement therapies: A Queensland study. Substance Use & Misuse, 47(1), 78–85. doi:10.3109/10826084.2011.629017
   PubMed Web of Science ®Google Scholar
• Strang, J., Groshkova, T., & Metrebian, N. (2012). New heroin-assisted treatment: Recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction.
   Google Scholar
• Vicknasingam, B., Mazlan, M., Schottenfeld, R., & Chawarski, M. (2010). Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug and Alcohol Dependence, 111(1–2), 44–49. doi:10.1016/j.drugalcdep.2010.03.014
   PubMed Web of Science ®Google Scholar
• Vidal-Trecan, G., Varescon, I., Nabet, N., & Boissonnas, A. (2003). Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug and Alcohol Dependence, 69(2), 175–181. doi:10.1016/S0376-8716(02)00312-5
   PubMed Web of Science ®Google Scholar
• Vijay, A., Bazazi, A., Yee, I., Kamarulzaman, A., & Altice, F. (2015). Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia. Journal of Substance Abuse Treatment, 54, 29–36.
   PubMed Web of Science ®Google Scholar
• Yokell, M., Zaller, N., Green, T., & Rich, J. (2011). Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Current Drug Abuse Reviews, 4(1), 28–41.
   PubMedGoogle Scholar